LLY

1,112.74

+0.39%↑

JNJ

240.64

+1.22%↑

ABBV

235.27

+0.77%↑

UNH

404.21

-0.8%↓

MRK

121.24

+1.85%↑

LLY

1,112.74

+0.39%↑

JNJ

240.64

+1.22%↑

ABBV

235.27

+0.77%↑

UNH

404.21

-0.8%↓

MRK

121.24

+1.85%↑

LLY

1,112.74

+0.39%↑

JNJ

240.64

+1.22%↑

ABBV

235.27

+0.77%↑

UNH

404.21

-0.8%↓

MRK

121.24

+1.85%↑

LLY

1,112.74

+0.39%↑

JNJ

240.64

+1.22%↑

ABBV

235.27

+0.77%↑

UNH

404.21

-0.8%↓

MRK

121.24

+1.85%↑

LLY

1,112.74

+0.39%↑

JNJ

240.64

+1.22%↑

ABBV

235.27

+0.77%↑

UNH

404.21

-0.8%↓

MRK

121.24

+1.85%↑

Search

Revvity Inc

Open

BrancheGesundheitswesen

106.26 6.38

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

98.97

Max

106.68

Schlüsselkennzahlen

By Trading Economics

Einkommen

-58M

41M

Verkäufe

-61M

711M

KGV

Branchendurchschnitt

47.615

49.712

EPS

1.06

Dividendenrendite

0.28

Gewinnspanne

5.726

Angestellte

11,000

EBITDA

-38M

180M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+4.76% upside

Dividenden

By Acuity

Dividendenrendite

Branchendurchschnitt

0.28%

2.36%

Nächstes Ergebnis

27. Juli 2026

Nächste Dividendenausschüttung

7. Aug. 2026

Nächstes Ex-Dividendendatum

17. Juli 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.4B

11B

Vorheriger Eröffnungskurs

99.88

Vorheriger Schlusskurs

106.26

Nachrichtenstimmung

By Acuity

19%

81%

36 / 342 Ranking in Healthcare

Revvity Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Über Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat